Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Jeffrey S. Weber, Geoffrey T. Gibney, Ragini R. Kudchadkar, Bin Yu, Pingyan Cheng, Alberto J. Martinez, Jodie Kroeger, Allison Richards, Lori McCormick, Valerie E. Moberg, Heather Cronin, Xiuhua Zhao, Michael J. Schell, Y. Ann Chen
Hōputu:	Artigo
Reo:	Ingarihi
I whakaputaina:	2016
Urunga tuihono:	https://doi.org/10.1158/2326-6066.cir-15-0193 https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab
mā: Weber, Jeffrey, me ētahi atu.
I whakaputaina: (2016)

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
mā: Weber, Jeffrey S., me ētahi atu.
I whakaputaina: (2013)

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
mā: Jeffrey S. Weber, me ētahi atu.
I whakaputaina: (2013)

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
mā: Tawbi, Hussein A., me ētahi atu.
I whakaputaina: (2018)

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
mā: Hussein A. Tawbi, me ētahi atu.
I whakaputaina: (2018)

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
mā: Postow, Michael A., me ētahi atu.
I whakaputaina: (2015)

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
mā: Michael A. Postow, me ētahi atu.
I whakaputaina: (2015)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
mā: Chapman, Paul B, me ētahi atu.
I whakaputaina: (2021)

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
mā: Morganna Freeman-Keller, me ētahi atu.
I whakaputaina: (2015)

Nivolumab plus Ipilimumab in Advanced Melanoma
mā: Jedd D. Wolchok, me ētahi atu.
I whakaputaina: (2013)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
mā: Jeffrey S. Weber, me ētahi atu.
I whakaputaina: (2017)

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
mā: Geoffrey T. Gibney, me ētahi atu.
I whakaputaina: (2014)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
mā: Wolchok, Jedd D., me ētahi atu.
I whakaputaina: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
mā: Jedd D. Wolchok, me ētahi atu.
I whakaputaina: (2021)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
mā: Matías E. Valsecchi
I whakaputaina: (2015)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
mā: James Larkin, me ētahi atu.
I whakaputaina: (2015)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
mā: Katy K. Tsai, me ētahi atu.
I whakaputaina: (2015)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
mā: Potluri, Ravi, me ētahi atu.
I whakaputaina: (2019)

Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma
mā: Larkin, James, me ētahi atu.
I whakaputaina: (2015)

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
mā: Wolchok, J.D., me ētahi atu.
I whakaputaina: (2017)

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
mā: Jedd D. Wolchok, me ētahi atu.
I whakaputaina: (2017)

Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma
mā: Anthony V. Serritella, me ētahi atu.
I whakaputaina: (2023)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
mā: Asher, Nethanel, me ētahi atu.
I whakaputaina: (2020)

Usefulness of nivolumab plus ipilimumab immunotherapy for metastatic uveal melanoma
mā: Miles, Brittany, me ētahi atu.
I whakaputaina: (2020)

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
mā: James Larkin, me ētahi atu.
I whakaputaina: (2019)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
mā: Nethanel Asher, me ētahi atu.
I whakaputaina: (2020)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
mā: Brohl, Andrew S., me ētahi atu.
I whakaputaina: (2016)

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
mā: Douglas B. Johnson, me ētahi atu.
I whakaputaina: (2014)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
mā: Tawbi, Hussein A, me ētahi atu.
I whakaputaina: (2021)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
mā: Hussein A. Tawbi, me ētahi atu.
I whakaputaina: (2021)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
mā: Hantel, Andrew, me ētahi atu.
I whakaputaina: (2018)

Ipilimumab and Nivolumab-Induced Colitis in a Patient With Recurrent Metastatic Melanoma
mā: Moein, Hamid-Reza, me ētahi atu.
I whakaputaina: (2021)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
mā: Fukumoto, Takeshi, me ētahi atu.
I whakaputaina: (2022)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
mā: Homicsko, Krisztian, me ētahi atu.
I whakaputaina: (2022)

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
mā: Andrew Hantel, me ētahi atu.
I whakaputaina: (2018)

Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
mā: Matteo S. Carlino, me ētahi atu.
I whakaputaina: (2016)

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
mā: Johnson, Douglas B., me ētahi atu.
I whakaputaina: (2015)

Development of Nivolumab/Ipilimumab-Associated Autoimmune Nephritis during Steroid Therapy
mā: Gebauer, Ellen, me ētahi atu.
I whakaputaina: (2021)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
mā: Ian M. Bouligny, me ētahi atu.
I whakaputaina: (2025)

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
mā: Shoushtari, Alexander N., me ētahi atu.
I whakaputaina: (2017)